XFOR
X4 Pharmaceuticals, Inc.
Price Chart
Latest Quote
$3.90
-0.12 (-2.99%)
Current Price
| Previous Close | $4.02 |
| Open | $4.03 |
| Day High | $4.04 |
| Day Low | $3.78 |
| Volume | 538,266 |
Stock Information
| Shares Outstanding | 94.32M |
| Total Debt | $77.25M |
| Cash Equivalents | $233.72M |
| Revenue | $9.01M |
| Net Income | $-99.72M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $360.30M |
| EPS (TTM) | $-2.06 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $203.83M |
| Sales | $9.01M |
| Income | $-99.72M |
| Book/sh | $1.79 |
| Cash/sh | $2.48 |
| Employees | 45 |
Financial Ratios
| Quick Ratio | 9.88 |
| Current Ratio | 10.18 |
| Debt/Eq | 45.86 |
Returns & Margins
| ROA | -28.33% |
| ROE | -104.21% |
| Gross Margin | 81.82% |
| Operating Margin | -748.49% |
Ownership
| Insider Ownership | 0.54% |
| Institutional Ownership | 99.77% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.66 |
| P/S | 39.97 |
| P/B | 2.14 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $11.60 |
Technical Indicators
| SMA20 | $4.07 |
| SMA50 | $4.05 |
| SMA200 | $3.83 |
| RSI | 46.05 |
| ATR | 0.2929 |
| Shares Float | 57.53M |
| Short Float | 5.85% |
| Short Ratio | 5.54 |
| Volatility | 0.35 |
| Rel Volume | 0.40 |
Performance History
| Week | -13.38% |
| Month | -5.45% |
| Quarter | -7.73% |
| 6 Months | +1.33% |
| YTD | -1.80% |
| Year | +151.32% |
| 3 Years | -93.30% |
| 5 Years | -97.99% |
| 10 Years | -99.85% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $3.82 | 461,900 |
| 2026-07-16 | $3.83 | 504,500 |
| 2026-07-15 | $3.90 | 539,300 |
| 2026-07-14 | $4.02 | 1,140,800 |
| 2026-07-13 | $4.05 | 642,300 |
| 2026-07-10 | $4.41 | 918,400 |
| 2026-07-09 | $3.96 | 447,300 |
| 2026-07-08 | $3.96 | 464,600 |
| 2026-07-07 | $3.94 | 528,200 |
| 2026-07-06 | $4.03 | 542,500 |
| 2026-07-02 | $4.13 | 678,900 |
| 2026-07-01 | $4.09 | 807,000 |
| 2026-06-30 | $4.67 | 1,104,500 |
| 2026-06-29 | $4.23 | 591,600 |
| 2026-06-26 | $4.02 | 10,479,400 |
| 2026-06-25 | $3.99 | 633,000 |
| 2026-06-24 | $4.09 | 686,400 |
| 2026-06-23 | $4.00 | 352,700 |
| 2026-06-22 | $4.12 | 438,100 |
| 2026-06-18 | $4.22 | 866,300 |
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
đ° Latest News
How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress
Simply Wall St. âĸ 2026-05-21T04:33:35Z
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now
Zacks âĸ 2026-05-20T13:55:02Z
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2026-05-18T16:00:03Z
Here is Why X4 Pharmaceuticals (XFOR)Â is Among the Unrivaled Penny Stocks to Buy Now
Insider Monkey âĸ 2026-05-14T17:39:03Z
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-06T12:25:10Z
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-05T12:25:04Z
One X4 Pharmaceuticals Insider Raised Their Stake In The Previous Year
Simply Wall St. âĸ 2026-04-09T13:47:20Z
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates
Zacks âĸ 2026-03-17T12:25:02Z
X4 Pharmaceuticals: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-17T11:34:28ZProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
Zacks âĸ 2026-03-12T14:15:01Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $5,757,000 | $797,000 | $0 | $0 |
| Cost Of Revenue | $5,757,000 | $797,000 | $0 | $0 |
| Total Revenue | $35,113,000 | $2,557,000 | $0 | $0 |
| Operating Revenue | $35,113,000 | $2,557,000 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $8,876,000 | $8,768,000 | $5,777,000 | $3,993,000 |
| Total Expenses | $121,996,000 | $143,958,000 | $107,522,000 | $88,078,000 |
| Other Income Expense | $12,025,000 | $107,260,000 | $7,628,000 | $-1,987,000 |
| Other Non Operating Income Expenses | $-753,000 | $332,000 | $554,000 | $-4,197,000 |
| Net Non Operating Interest Income Expense | $-4,300,000 | $-2,999,000 | $-1,195,000 | $-3,774,000 |
| Interest Expense Non Operating | $8,876,000 | $8,768,000 | $5,777,000 | $3,993,000 |
| Operating Expense | $116,239,000 | $143,161,000 | $107,522,000 | $88,078,000 |
| General And Administrative Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-79,199,000 | $-37,450,000 | $-101,167,000 | $-93,867,000 |
| Net Interest Income | $-4,300,000 | $-2,999,000 | $-1,195,000 | $-3,774,000 |
| Interest Income | $4,576,000 | $5,769,000 | $4,582,000 | $219,000 |
| Normalized Income | $-89,293,620 | $-121,923,120 | $-106,755,460 | $-95,612,900 |
| Net Income From Continuing And Discontinued Operation | $-79,199,000 | $-37,450,000 | $-101,167,000 | $-93,867,000 |
| Total Operating Income As Reported | $-86,883,000 | $-36,401,000 | $-107,522,000 | $-87,569,000 |
| Net Income Common Stockholders | $-79,199,000 | $-37,450,000 | $-101,167,000 | $-96,413,000 |
| Net Income | $-79,199,000 | $-37,450,000 | $-101,167,000 | $-93,867,000 |
| Net Income Including Noncontrolling Interests | $-79,199,000 | $-37,450,000 | $-101,167,000 | $-93,867,000 |
| Net Income Continuous Operations | $-79,199,000 | $-37,450,000 | $-101,167,000 | $-93,867,000 |
| Pretax Income | $-79,158,000 | $-37,140,000 | $-101,089,000 | $-93,839,000 |
| Special Income Charges | $0 | $105,000,000 | $0 | $509,000 |
| Interest Income Non Operating | $4,576,000 | $5,769,000 | $4,582,000 | $219,000 |
| Operating Income | $-86,883,000 | $-141,401,000 | $-107,522,000 | $-88,078,000 |
| Gross Profit | $29,356,000 | $1,760,000 | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $-1.87 | $-5.70 | $-17.07 | $-45.60 |
| Basic EPS | $-1.87 | $-5.70 | $-17.07 | $-45.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $2,683,380 | $22,454,880 | $1,485,540 | $464,100 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-81,783,000 | $-134,504,000 | $-101,967,000 | $-91,543,000 |
| Total Unusual Items | $12,778,000 | $106,928,000 | $7,074,000 | $2,210,000 |
| Total Unusual Items Excluding Goodwill | $12,778,000 | $106,928,000 | $7,074,000 | $2,210,000 |
| Reconciled Depreciation | $1,277,000 | $796,000 | $419,000 | $513,000 |
| EBITDA (Bullshit earnings) | $-69,005,000 | $-27,576,000 | $-94,893,000 | $-89,333,000 |
| EBIT | $-70,282,000 | $-28,372,000 | $-95,312,000 | $-89,846,000 |
| Diluted Average Shares | $42,292,818 | $6,702,066 | $5,927,082 | $2,117,533 |
| Basic Average Shares | $42,292,818 | $6,702,066 | $5,927,082 | $2,117,533 |
| Diluted NI Availto Com Stockholders | $-79,199,000 | $-37,450,000 | $-101,167,000 | $-96,413,000 |
| Tax Provision | $41,000 | $310,000 | $78,000 | $28,000 |
| Gain On Sale Of Ppe | $0 | $105,000,000 | $0 | $509,000 |
| Gain On Sale Of Security | $12,778,000 | $1,928,000 | $7,074,000 | $1,701,000 |
| Research And Development | $72,723,000 | $81,643,000 | $72,017,000 | $61,058,000 |
| Selling General And Administration | $43,516,000 | $61,518,000 | $35,505,000 | $27,020,000 |
| Otherunder Preferred Stock Dividend | - | $0 | $0 | $2,546,000 |
| Impairment Of Capital Assets | - | - | $0 | $0 |
| Other Gand A | - | - | - | - |
Fetched: 2026-07-08
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $159,689,000 | $-5,202,000 | $33,748,000 | $56,700,000 |
| Total Assets | $290,461,000 | $146,447,000 | $147,258,000 | $155,586,000 |
| Total Non Current Assets | $28,884,000 | $34,272,000 | $25,182,000 | $26,909,000 |
| Other Non Current Assets | $692,000 | $2,080,000 | $1,436,000 | $1,225,000 |
| Goodwill And Other Intangible Assets | $26,601,000 | $27,351,000 | $17,351,000 | $17,351,000 |
| Other Intangible Assets | $9,250,000 | $10,000,000 | - | - |
| Current Assets | $261,577,000 | $112,175,000 | $122,076,000 | $128,677,000 |
| Other Current Assets | $3,527,000 | $5,588,000 | $7,298,000 | $5,807,000 |
| Inventory | $4,479,000 | $2,817,000 | $0 | - |
| Receivables | $573,000 | $1,710,000 | $562,000 | $1,152,000 |
| Accounts Receivable | $573,000 | $1,070,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $252,998,000 | $102,060,000 | $114,216,000 | $121,718,000 |
| Cash And Cash Equivalents | $217,049,000 | $55,699,000 | $99,216,000 | $121,718,000 |
| Other Receivables | - | $640,000 | $562,000 | $1,152,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $77,285,000 | $78,086,000 | $58,281,000 | $38,420,000 |
| Long Term Debt And Capital Lease Obligation | $76,291,000 | $76,835,000 | $57,182,000 | $35,907,000 |
| Long Term Debt | $76,291,000 | $75,425,000 | $54,570,000 | $32,304,000 |
| Current Debt And Capital Lease Obligation | $994,000 | $1,251,000 | $1,099,000 | $2,513,000 |
| Net Debt | - | $19,726,000 | - | - |
| Current Debt | - | - | - | $1,315,000 |
| Other Current Borrowings | - | - | - | $1,315,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $104,171,000 | $124,298,000 | $96,159,000 | $81,535,000 |
| Total Non Current Liabilities Net Minority Interest | $78,414,000 | $91,421,000 | $73,297,000 | $59,211,000 |
| Other Non Current Liabilities | $525,000 | $831,000 | $432,000 | $173,000 |
| Derivative Product Liabilities | $977,000 | $13,755,000 | $15,683,000 | $23,131,000 |
| Non Current Deferred Liabilities | $621,000 | $0 | - | - |
| Current Liabilities | $25,757,000 | $32,877,000 | $22,862,000 | $22,324,000 |
| Current Deferred Liabilities | $464,000 | $0 | - | - |
| Payables And Accrued Expenses | $19,996,000 | $18,573,000 | $13,568,000 | $13,219,000 |
| Payables | $5,696,000 | $8,621,000 | $8,947,000 | $7,777,000 |
| Accounts Payable | $5,696,000 | $8,621,000 | $8,947,000 | $7,777,000 |
| Equity | ||||
| Common Stock Equity | $186,290,000 | $22,149,000 | $51,099,000 | $74,051,000 |
| Total Equity Gross Minority Interest | $186,290,000 | $22,149,000 | $51,099,000 | $74,051,000 |
| Stockholders Equity | $186,290,000 | $22,149,000 | $51,099,000 | $74,051,000 |
| Gains Losses Not Affecting Retained Earnings | $-109,000 | $-122,000 | $-119,000 | $-119,000 |
| Other Equity Adjustments | $-109,000 | $-122,000 | $-119,000 | $-119,000 |
| Retained Earnings | $-594,554,000 | $-515,355,000 | $-477,905,000 | $-376,738,000 |
| Other | ||||
| Ordinary Shares Number | $90,906,920 | $5,698,231 | $5,581,153 | $4,055,574 |
| Share Issued | $90,906,920 | $5,698,231 | $5,581,153 | $4,055,574 |
| Tangible Book Value | $159,689,000 | $-5,202,000 | $33,748,000 | $56,700,000 |
| Invested Capital | $262,581,000 | $97,574,000 | $105,669,000 | $107,670,000 |
| Working Capital | $235,820,000 | $79,298,000 | $99,214,000 | $106,353,000 |
| Capital Lease Obligations | $994,000 | $2,661,000 | $3,711,000 | $4,801,000 |
| Total Capitalization | $262,581,000 | $97,574,000 | $105,669,000 | $106,355,000 |
| Additional Paid In Capital | $780,862,000 | $537,620,000 | $528,956,000 | $450,786,000 |
| Capital Stock | $91,000 | $6,000 | $167,000 | $122,000 |
| Common Stock | $91,000 | $6,000 | $167,000 | $122,000 |
| Preferred Stock | $0 | $0 | $0 | - |
| Non Current Deferred Revenue | $621,000 | $0 | - | - |
| Long Term Capital Lease Obligation | $0 | $1,410,000 | $2,612,000 | $3,603,000 |
| Current Deferred Revenue | $464,000 | $0 | - | - |
| Current Capital Lease Obligation | $994,000 | $1,251,000 | $1,099,000 | $1,198,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,303,000 | $13,053,000 | $8,195,000 | $6,592,000 |
| Current Accrued Expenses | $14,300,000 | $9,952,000 | $4,621,000 | $5,442,000 |
| Goodwill | $17,351,000 | $17,351,000 | $17,351,000 | $17,351,000 |
| Net PPE | $1,591,000 | $4,841,000 | $6,395,000 | $8,333,000 |
| Accumulated Depreciation | $-1,232,000 | $-1,903,000 | $-1,619,000 | $-1,228,000 |
| Gross PPE | $2,823,000 | $6,744,000 | $8,014,000 | $9,561,000 |
| Leases | $228,000 | $228,000 | $228,000 | $228,000 |
| Other Properties | $1,426,000 | $4,734,000 | $6,301,000 | $7,868,000 |
| Machinery Furniture Equipment | $1,169,000 | $1,782,000 | $1,485,000 | $1,465,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $579,000 | $680,000 | $0 | - |
| Work In Process | $2,518,000 | $608,000 | $0 | - |
| Raw Materials | $1,382,000 | $1,529,000 | $0 | - |
| Other Short Term Investments | $35,949,000 | $46,361,000 | $15,000,000 | $0 |
Fetched: 2026-07-08
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-88,618,000 | $-138,227,000 | $-96,572,000 | $-77,205,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-85,618,000 | $-130,901,000 | $-96,512,000 | $-77,102,000 |
| Cash Flow From Continuing Operating Activities | $-85,618,000 | $-130,901,000 | $-96,512,000 | $-77,102,000 |
| Operating Gains Losses | $-12,778,000 | $-106,928,000 | $-7,074,000 | $2,881,000 |
| Investing Activities | ||||
| Capital Expenditure | $-3,000,000 | $-7,326,000 | $-60,000 | $-103,000 |
| Investing Cash Flow | $8,154,000 | $66,990,000 | $-14,883,000 | $-103,000 |
| Cash Flow From Continuing Investing Activities | $8,154,000 | $66,990,000 | $-14,883,000 | $-103,000 |
| Net Other Investing Changes | - | $105,000,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $238,530,000 | $0 | $59,999,000 | $122,631,000 |
| Financing Cash Flow | $238,628,000 | $20,294,000 | $88,516,000 | $117,230,000 |
| Cash Flow From Continuing Financing Activities | $238,628,000 | $20,294,000 | $88,516,000 | $117,230,000 |
| Net Common Stock Issuance | $238,530,000 | $0 | $59,999,000 | $122,631,000 |
| Common Stock Issuance | $238,530,000 | $0 | $59,999,000 | $122,631,000 |
| Repurchase Of Capital Stock | - | - | $0 | $0 |
| Net Other Financing Charges | - | - | $-631,000 | $-4,814,000 |
| Other | ||||
| Repayment Of Debt | $0 | $0 | $-2,064,000 | $-795,000 |
| Issuance Of Debt | $0 | $20,000,000 | $22,500,000 | $0 |
| Interest Paid Supplemental Data | $8,053,000 | $7,766,000 | $4,604,000 | $3,006,000 |
| End Cash Position | $217,852,000 | $56,475,000 | $100,248,000 | $123,028,000 |
| Beginning Cash Position | $56,475,000 | $100,248,000 | $123,028,000 | $83,108,000 |
| Effect Of Exchange Rate Changes | $213,000 | $-156,000 | $99,000 | $-105,000 |
| Changes In Cash | $161,164,000 | $-43,617,000 | $-22,879,000 | $40,025,000 |
| Proceeds From Stock Option Exercised | $98,000 | $294,000 | $8,712,000 | $208,000 |
| Net Issuance Payments Of Debt | $0 | $20,000,000 | $20,436,000 | $-795,000 |
| Net Long Term Debt Issuance | $0 | $20,000,000 | $20,436,000 | $-795,000 |
| Long Term Debt Payments | $0 | $0 | $-2,064,000 | $-795,000 |
| Long Term Debt Issuance | $0 | $20,000,000 | $22,500,000 | $0 |
| Net Investment Purchase And Sale | $11,154,000 | $-30,684,000 | $-14,823,000 | $0 |
| Sale Of Investment | $74,542,000 | $26,450,000 | $2,000,000 | $0 |
| Purchase Of Investment | $-63,388,000 | $-57,134,000 | $-16,823,000 | $0 |
| Net Intangibles Purchase And Sale | $-3,000,000 | $-7,000,000 | $0 | $0 |
| Purchase Of Intangibles | $-3,000,000 | $-7,000,000 | $0 | $0 |
| Net PPE Purchase And Sale | $0 | $-326,000 | $-60,000 | $-103,000 |
| Purchase Of PPE | $0 | $-326,000 | $-60,000 | $-103,000 |
| Change In Working Capital | $-2,576,000 | $2,675,000 | $344,000 | $5,736,000 |
| Change In Other Working Capital | $1,085,000 | - | - | - |
| Change In Other Current Liabilities | $-1,740,000 | $-1,004,000 | $-1,128,000 | $-882,000 |
| Change In Payables And Accrued Expense | $-5,004,000 | $6,883,000 | $2,842,000 | $7,228,000 |
| Change In Accrued Expense | $-2,025,000 | $7,169,000 | $1,608,000 | $3,803,000 |
| Change In Payable | $-2,979,000 | $-286,000 | $1,234,000 | $3,425,000 |
| Change In Account Payable | $-2,979,000 | $-286,000 | $1,234,000 | $3,425,000 |
| Change In Prepaid Assets | $4,248,000 | $683,000 | $-1,370,000 | $-610,000 |
| Change In Inventory | $-1,662,000 | $-2,817,000 | $0 | $0 |
| Change In Receivables | $497,000 | $-1,070,000 | $0 | $0 |
| Changes In Account Receivables | $497,000 | $-1,070,000 | $0 | $0 |
| Other Non Cash Items | $3,360,000 | $1,802,000 | $2,279,000 | $2,436,000 |
| Stock Based Compensation | $4,298,000 | $8,204,000 | $8,687,000 | $5,199,000 |
| Depreciation Amortization Depletion | $1,277,000 | $796,000 | $419,000 | $513,000 |
| Depreciation And Amortization | $1,277,000 | $796,000 | $419,000 | $513,000 |
| Gain Loss On Investment Securities | $-12,778,000 | $-1,928,000 | $-7,074,000 | $2,881,000 |
| Net Income From Continuing Operations | $-79,199,000 | $-37,450,000 | $-101,167,000 | $-93,867,000 |
| Common Stock Payments | - | - | $0 | $0 |
| Change In Other Current Assets | - | - | $0 | $0 |
| Asset Impairment Charge | - | - | $0 | $0 |
Fetched: 2026-07-08